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Abstract: ABSTRACT 
Background 
Arrhythmogenic right ventricular Cardiomyopathy/Dysplasia (ARVC/D) is a genetic disease 
predominantly caused by desmosomal gene mutations that account for only ~50% of cases. RYR2 gene 
mutations usually cause Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) but have 
been associated with peculiar phenotype named ARVC2.  
Objectives 
We aim to determine the prevalence and phenotype associated with RYR2 mutations in a large 
ARVC/D population.  
Methods 
We analyzed the whole RYR2 coding sequence by Sanger sequencing in 64 ARVC/D probands without 
desmosomal gene mutations.  
 
Results 
 We have identified six rare missense variants p.P1583S, p.A2213S, p.G2367R, p.Y2932H, p.V3219M 
and p.L4670V. It corresponds to a prevalence of 9% of rare RYR2 variants in ARVC/D population (6 
probands/64) that is significantly higher than the estimated rate of rare RYR2 variants in control 
(Fisher test, p=0.03). Phenotypes associated with RYR2 variants were similar to desmosome-related 
ARVC/D, associating typical ECG abnormalities at rest, frequent monomorphic ventricular tachycardia, 
right ventricular dilatation, wall motion abnormalities and fibro-fatty replacement when 
histopathological examination was available. 
 
Conclusion  
In this first systematic screening of the whole coding region of the RYR2 gene in a large ARVC/D cohort 
without mutation in desmosomal genes, we show that putative RYR2 mutations are frequent (9% of 
ARVC/D probands) and are associated with a conventional phenotype of ARVC/D, in contrast with 
previous findings. The results support the role of RYR2 gene in conventional ARVC/D. 
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“In this first systematic screening of the whole coding region of the RYR2 gene in a 
large ARVC/D cohort without mutation in desmosomal genes, we show that putative 
RYR2 mutations are frequent (9% of ARVC/D probands) and are associated with a 
conventional phenotype of ARVC/D, in contrast with previous findings.” 
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analysis to the 1994 Task Force criteria, and indicate why. 
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ABSTRACT 1 
Background 2 
Arrhythmogenic right ventricular Cardiomyopathy/Dysplasia (ARVC/D) is a genetic 3 
disease predominantly caused by desmosomal gene mutations that account for only ~50% of 4 
cases. RYR2 gene mutations usually cause Catecholaminergic Polymorphic Ventricular 5 
Tachycardia (CPVT) but have been associated with peculiar phenotype named ARVC2.  6 
Objectives 7 
We aim to determine the prevalence and phenotype associated with RYR2 mutations in a large 8 
ARVC/D population.  9 
Methods 10 
We analyzed the whole RYR2 coding sequence by Sanger sequencing in 64 ARVC/D 11 
probands without desmosomal gene mutations.  12 
 13 
Results 14 
 We have identified six rare missense variants p.P1583S, p.A2213S, p.G2367R, 15 
p.Y2932H, p.V3219M and p.L4670V. It corresponds to a prevalence of 9% of rare RYR2 16 
variants in ARVC/D population (6 probands/64) that is significantly higher than the estimated 17 
rate of rare RYR2 variants in control (Fisher test, p=0.03). Phenotypes associated with RYR2 18 
variants were similar to desmosome-related ARVC/D, associating typical ECG abnormalities 19 
at rest, frequent monomorphic ventricular tachycardia, right ventricular dilatation, wall 20 
motion abnormalities and fibro-fatty replacement when histopathological examination was 21 
available. 22 
 23 
5 
 
Conclusion  1 
In this first systematic screening of the whole coding region of the RYR2 gene in a large 2 
ARVC/D cohort without mutation in desmosomal genes, we show that putative RYR2 3 
mutations are frequent (9% of ARVC/D probands) and are associated with a conventional 4 
phenotype of ARVC/D, in contrast with previous findings. The results support the role of 5 
RYR2 gene in conventional ARVC/D. 6 
 7 
 8 
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RV: right ventricle  1 
RVOT: right ventricle outflow tract 2 
RYR2: Ryanodine receptor type 2  3 
SNP: single nucleotide polymorphism 4 
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TFC: Task Force Criteria 6 
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INTRODUCTION   1 
Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D) is a rare cardiac 2 
muscle disorder characterised by progressive fibro-fatty replacement of the myocardium. The 3 
right ventricle is predominantly affected but left ventricular involvement is also present in 4 
more than half of the cases
1
. These structural alterations can lead to ventricular arrhythmias 5 
and heart failure. ARVC/D is a frequent cause of sudden death in young people and athletes. 6 
The diagnosis of ARVC/D is currently based on the presence of major and minor standardised 7 
Task Force criteria (TFC) that consider ventricular arrhythmias episodes, electrocardiographic 8 
abnormalities, right ventricular function and morphology, histopathology, family history and 9 
genetic status
2
. 10 
ARVC/D is usually inherited as an autosomal dominant disease with reduced penetrance and 11 
variable expression. So far, the major genes involved in ARVC/D encode components of the 12 
cardiac desmosome: plakophilin-2 (PKP2)
3
, desmoglein-2 (DSG2)
4,5
, plakoglobin (JUP)
6
, 13 
desmoplakin (DSP)
7
 and desmocollin-2 (DSC2)
8,9
. Comprehensive mutation screening of the 14 
five main desmosomal ARVC/D genes can detect genetic abnormalities in at least 40-50% of 15 
probands
10
. Non-desmosomal genes have been also associated with ARVC/D phenotypes 16 
including the cardiac ryanodine receptor type 2 gene (RYR2)
11
, the transforming growth factor 17 
beta 3 gene (TGFB3)
12
, the TMEM43 gene
13
 and more recently the lamin A/C (LMNA)
14
, the 18 
titin (TTN)
15
, the desmin (DES)
16
 and the phospholamban (PLN)
17
 genes. Mutations in the 19 
RYR2 gene are usually associated with catecholaminergic polymorphic ventricular tachycardia 20 
(CPVT), a rare and severe inherited arrhythmia without structural cardiac abnormality
18,19
 21 
(http://www.fsm.it/cardmoc/). 22 
RYR2 is one of the largest human genes (105 exons) encoding a mRNA of 16365 bp 23 
(NM_021991.2). Nava et al reported in 1988 a family with autosomal dominant form of right 24 
ventricular cardiomyopathy (supported by histological data) associated with polymorphic 25 
8 
 
ventricular tachycardia induced by exercise stress testing and juvenile sudden death
20
. 1 
Rampazzo et al mapped then the locus to chromosome 1q42-q43 and identified RYR2 2 
mutations in four independent families with the same clinical presentation of ARVC/D 3 
(named ARVC/D2)
11,21
. This clinical presentation differs from desmosome-related forms of 4 
ARVC/D and is rather close to CPVT because of the presence of effort-induced ventricular 5 
arrhythmias, its high penetrance and a 1:1 sex ratio. The association between typical form of 6 
ARVC/D and RYR2 mutations remains unclear and the prevalence of RYR2 mutations in the 7 
ARVC/D population remains unknown since very few mutations have been associated to 8 
ARVC/D
11,22-24
.  9 
In this study, we aimed to determine the prevalence of RYR2 mutations in a large cohort of 64 10 
well clinically characterised ARVC/D probands for whom mutations in PKP2, DSG2, DSP, 11 
DSC2 and JUP were previously excluded. Sequencing of the entire coding region of RYR2 in 12 
these ARVC/D probands led to the identification of 6 putative missense mutations in 6 13 
unrelated probands. The pathogenic role of the variations is discussed as well as the 14 
consequences for clinical practice.  15 
METHODS 16 
Patients  17 
This multicenter prospective study included a cohort of unrelated probands recruited in 18 
France and Switzerland with a diagnosis of ARVC/D according to the TFC used at time of 19 
enrolment
25
 and then focussed on 64 probands for whom no mutation were identified in 20 
PKP2, DSG2, DSP, JUP and DSC2 genes
10
.  21 
Clinical evaluation of all probands was performed as described previously
10
 and included: 22 
evaluation of personal and familial history, physical examination, 12-lead standard ECG, 23 
standard echocardiography, cardiac Magnetic Resonance Imaging (MRI) or right ventricular 24 
(RV) angiography, 24-hours ambulatory electrocardiogram (ECG) and signal-averaged-25 
9 
 
ECG
10
. Baseline exercise test was performed in all probands, except in very particular 1 
situations requiring urgent therapeutic management (such as implantable cardiac defibrillator 2 
or anti-arrhythmic drugs). Electrophysiologic (EP) study was performed when considered 3 
clinically relevant by the physician, according to the following protocol: 2 different sites, 2 4 
rates, with up to 3 extra stimuli, at baseline and with infusion of isoproterenol. In the case of 5 
cardiac transplant, pathological analysis of the explanted heart was performed. Clinical 6 
evaluation of relatives was performed when available. This study was approved by the Pitié-7 
Salpêtrière Hospital ethical committee (CPP) and written informed consent was obtained from 8 
all individuals.  9 
Genetic analysis 10 
For each proband, the 105 exons and intron-exon junctions of the RYR2 gene were amplified 11 
from genomic DNA (OMIM 180902, transcript: NM_021991.2, protein: 4967 AA, Q92736-1, 12 
primer sequences available upon request). The analysis of the entire coding sequence of RYR2 13 
was performed by direct sequencing on an ABI 3130 DNA sequencer (PE Applied 14 
Biosystems®, Foster City, USA).  15 
When unreported variant were detected, they were searched among 400 chromosomes from 16 
ethnically matched and healthy control subjects (Caucasian n=400 or Maghrebian n=134) by 17 
direct sequencing or by denaturating high-performance liquid chromatography (Wave 18 
Transgenomic Inc®, Cambridge,USA).  19 
Upon identification, the likelihood of a pathogenic effect of an unreported RYR2 variant was 20 
based on (i) the absence of the variant in the control population and an allele frequency 21 
inferior to 1 / 10 000 in the databases NCBI SNPs, 1000 Genome and Exome Variant Server 22 
(http://www.ncbi.nlm.nih.gov/snp, http///browser.1000genomes.org/index.html, 23 
http://evs.gs.washington.edu/EVS), (ii) the conservation of the mutated residue among species 24 
and RYR isoforms and (iii) the predicted effect of the mutation by three appropriate software 25 
10 
 
(Polyphen2, SIFT, SNPsandGO  http://genetics.bwh.harvard.edu/pph2/, 1 
http://sift.bii.astar.edu.sg/, http://snps-and-go.biocomp.unibio.it/snps-and-go/ ). The 2 
segregation analysis within the family was performed when the relatives DNAs and clinical 3 
data were available.  4 
Statistical Analysis 5 
The frequency of the “genetic background noise” of rare RYR2 missense variants in the 6 
general population was estimated using data from the Exome Variant Server database (EVS). 7 
By using the coverage data available in EVS website, we find that 25938 positions covering 8 
the RYR2 exons and introns boundaries had sufficient sequence coverage to be genotyped in 9 
5818 individuals in average (99.9% of the coding sequence). We considered as a rare 10 
missense variant, each missense variant observed at maximum 5 times among the cohort of 11 
individuals genotyped in EVS.  12 
The occurrence of these rare variations were added together and divided by the mean of allele 13 
population to reach a theorical prevalence of rare variations in RYR2 in EVS, used as control 14 
population. The prevalence of rare RYR2 variations in our cohort (128 alleles or 64 patients) 15 
was then compared with the prevalence of RYR2 variations found in the population analysed 16 
in EVS (11636 alleles or 5818 individuals). We decided to pool both European and African 17 
ancestry for the comparison, first since our population of patients comprises both European 18 
and African ancestry and second because frequency of rare variants of RYR2 is similar in 19 
European population and in African population. P value was calculated with Fisher’s exact 20 
test. Calculations were carried out using the graphpad software: 21 
http://www.graphpad.com/quickcalcs/contingency1/.   22 
 23 
RESULTS 24 
Clinical data 25 
11 
 
All probands fulfilled TFC used at time of enrolment
25
 and four fulfilled recent update TFC
2
. 1 
Clinical data are summarised in the tables 1 and S1. Pedigrees are presented in figure 1. 2 
Family A.  3 
The proband was a man presenting with aborted sudden cardiac death during intense effort, 4 
with ventricular fibrillation. Resting ECG showed in V1 an atypical conduction defect (figure 5 
2) and signal-averaged ECG detected late potentials. Cardiac imaging showed RV dilatation 6 
and multifocal wall-motion-abnormalities (WMA) with mild left ventricle (LV) abnormalities 7 
(table 1). He was found to carry a heterozygous RYR2 p.P1583S variant. The familial 8 
screening detected the variation in the affected father and a sister presenting with borderline 9 
phenotype while the three healthy relatives did not carry the variation. The father displayed 10 
frequent bimorphic ventricular ectopies and significant RV abnormalities on cardiac imaging. 11 
He also developed persistent atrial fibrillation needing cardioversion. The 17 year-old sister 12 
displayed a parietal block in V1 (figure 2) and mild RV abnormalities. Exercice test, EP study 13 
or isoproterenol test did not induced significant arrhythmia in the proband and his father.  14 
Family B. 15 
 The proband was an asymptomatic 43-year-old man. He fulfilled diagnosis criteria for 16 
ARVC/D with the presence of T-wave inversion (TWI) from V1 to V4, non-sustained 17 
monomorphic ventricular tachycardia (NSVT) recording during the 24-hour 3D-ECG 18 
monitoring, frequent ventricular ectopies with left bundle branch block (LBBB) morphology 19 
and superior axis and late potentials (figure 2 and 3). He displayed a mild RV dilatation  with 20 
global RV hypokinesia on cardiac-MRI. Electrophysiological mapping of the right ventricle 21 
showed a limited zone of scar within the inferior wall of the RV and the EP study triggered a 22 
monomorphic sustained ventricular tachycardia (SVT) with LBBB morphology and superior 23 
axis, suggesting ventricular tachycardia (VT) originating from this scar (figure 3). The 24 
molecular analysis of RYR2 found a p.L4670V heterozygous variation, also found in his 25 
12 
 
affected sister and his asymptomatic mother (figure 2). His sister displayed TWI from V1 to 1 
V3 without evidence of morphological abnormalities or ventricular arrhythmias (figure 2, 2 
table 1 and Supplementary table 1) while their mother only displayed positive late-potentials.   3 
Family C.  4 
This 59 years old male proband was a sporadic case that presented with presyncope and 5 
spontaneous ventricular arrhythmia, corresponding to monomorphic NSVT with a LBBB 6 
morphology and inferior axis. ECG showed complete right bundle branch block (RBBB). 7 
Echocardiography and cardiac MRI showed apical and RVOT dyskinesia although the RV 8 
was not significantly enlarged. He did not reach the 2010 diagnosis criteria and was then 9 
considered with a borderline diagnosis of ARVC/D. The EP study and the isoproterenol test 10 
were negative under beta-blockers. The RYR2 p.G2367R heterozygous variation was 11 
identified. No DNA from relatives was available. 12 
Family D.  13 
The proband was a sporadic case that presented with palpitations and several episodes of 14 
syncope since the age of 35. ECG showed TWI from V1 to V3 and late potentials (figure 2). 15 
He displayed spontaneous monomorphic sustained ventricular tachycardia of LBBB 16 
morphology. Cardiac imaging showed RV dilatation and dysfunction associated with apical 17 
and infero-basal WMA. Monomorphic NSVT with LBBB morphology and superior axis was 18 
triggered at EP study but not at exercise test and during isoproterenol test (figure 3). The 19 
p.A2213S heterozygous variation was identified in RYR2. One of the unaffected daughters, 12 20 
years of age, carried the variation. 21 
Family E.  22 
Proband was a sporadic case that presented with presyncope at the age of 41. Resting ECG 23 
showed TWI from V1 to V3 .The 24h-ECG monitoring detected frequent monomorphic 24 
ventricular ectopies (Vec) (figure2, table S1) decreasing during exercising. Cardiac imaging 25 
13 
 
showed WMA with dyskinesia and RV aneurysm but no RV dilatation and therefore did not 1 
reach the 2010 diagnostic criteria. The heterozygous p.V3219M variation in RYR2 was 2 
identified. 3 
Family F.  4 
Proband, a 39 years old woman, presented with palpitations and dyspnea. ECG showed 5 
epsilon wave, first-degree atrio-ventricular block, incomplete RBBB. She developed atrial 6 
fibrillation (figure 2). A 24h ECG monitoring and exercise test detected frequent polymorphic 7 
ventricular ectopies, increasing with effort (figure2, table S1). The EP study induced a 8 
syncopal polymorphic SVT. She developed a major RV dilatation with severe tricuspid 9 
regurgitation leading to end-stage heart failure that required heart transplantation. The 10 
anatomopathological study of the explanted heart confirmed typical histological features of 11 
ARVC/D with an extensive fibro-fatty replacement of the entire RV anterior wall associated 12 
with lymphocytes infiltration and important areas of fibro-fatty replacement within the LV 13 
wall (figure 4). A heterozygous p.Y2932H variation in RYR2 was identified. Familial 14 
screening detected the variation in two asymptomatic siblings. 15 
None of the six probands presented with bidirectional VT. Mutation carriers did not show 16 
NSVT nor SVT during exercice test (performed in three probands and two relatives) or during 17 
isoproterenol test (performed in four probands and one relative). 18 
Genetic analysis  19 
We identified six unique rare missense variants in RYR2 among our panel of 64 desmosome-20 
negative ARVC/D probands: p.P1583S, p.A2213S, p.G2367R, p.Y2932H, p.V3219M, 21 
p.L4670V (table 2). It corresponded to a yield of rare RYR2 variants of 9% (6/64) in our 22 
cohort. 23 
RYR2 is reported to be a relatively polymorphic gene by Jabbari et al
26
 . We decided therefore 24 
to analyse whether the prevalence of RYR2 variant in our cohort was higher or not than in the 25 
14 
 
general population. We estimated the prevalence of the genetic background noise of RYR2 1 
variants in the general population using the data from the Exome Variant Server. We 2 
considered as a rare RYR2 variant a variant observed at maximum 5 times in EVS, which is a 3 
conservative approach. We observed that a rare RYR2 variant was identified in 215/5818 4 
subjects in EVS (supplementary table 2). It corresponded to a rate of rare RYR2 variants of 5 
4% (215/5818) in EVS which was significantly lower to the 9% (6/64) observed in our cohort 6 
(Fisher test, p=0.0322).   7 
The variations p.A2213S, p.Y2932H and p.L4670V were novel.  8 
The p.P1583S variation is located in the cytoplasmic part of the protein, outside the hot spot 9 
of mutations of RYR2. The proline residue at position 1583 is highly conserved among species 10 
and isoforms of RYR (figure 5). The variation was predicted to be deleterious by all prediction 11 
software (table 2), and was absent among 400 control chromosomes and from the EVS and 12 
1000 genome databases. 13 
The p.G2367R was located in the cytoplasmic part of the protein in the second hot spot 14 
domain of RYR2 (central domain), close to the region of interaction with FKBP12.6, a major 15 
regulatory protein of RYR2. Moreover, this variant has been previously reported in association 16 
with hypertrophic cardiomyopathy and unexplained sudden cardiac death and functional 17 
studies showed a gain of function
27,28
. This variation was not found in 400 control 18 
chromosomes.  19 
The p.L4670V variation mapped to the transmembrane domain of the protein that participates 20 
to the pore of the calcium channel. This domain is a hot spot for RYR2 mutations, with more 21 
than 30 mutations published, all associated so far with CPVT or sudden death. Moreover, a 22 
p.L4670H variation has been recently reported in association with CPVT
26
. The variation 23 
affected a highly conserved leucine residue (figure 5), was predicted as deleterious by all 24 
15 
 
prediction softwares (table 2) and was found neither in 400 control chromosomes, nor in the 1 
variant databases.  2 
The p.A2213S, p.Y2932H, p.V3219M variations were located outside the hot spot of 3 
mutations of RYR2, and modified a not conserved amino acid. They were absent from 400 4 
control chromosomes but the p.V3219M variant was reported with a very low frequency 5 
(<0.0001%) from Exome Variant Server database.  6 
 7 
 8 
DISCUSSION   9 
Pathogenicity of RYR2 variants in ARVC/D 10 
We performed the first systematic screening of the whole RYR2 gene (105 exons and intron-11 
exon junctions) in a well clinically characterized ARVC/D cohort, after the exclusion of 12 
affected subjects harboring pathological mutations in either of the five desmosomal genes 13 
(PKP2, DSG2, DSP, JUP, DSC2). Among the 64 ARVC/D probands, we found a prevalence 14 
of rare RYR2 variants of 9%. Based on a conservative approach including the estimation of a 15 
“genetic background noise” of 4% in RYR2, we found a significantly higher frequency of 16 
RYR2 variants in our ARVC/D cohort.  17 
In the absence of functional studies, it remains difficult to classify any missense mutation as 18 
benign or pathogenic. Therefore, interpretation of our results was performed with 19 
considerable caution. We postulate that some of the new variants identified in our study are 20 
deleterious, either as a monogenic dominant mutation or through a modifier effect, while we 21 
cannot exclude the hypothesis that some variants may be very rare benign polymorphisms.  22 
The two variants, p.P1583S and p.L4670V were considered as highly probably pathogenic 23 
based on the conservation of the amino acid concerned, the absence of a large control 24 
population and the damaging effect predicted in silico. The familial studies showed that the 25 
16 
 
variants segregate with the phenotype but with reduced penetrance. The pathogenic effect of 1 
p.A2213S, p.G2367R, p.Y2932H, p.V3219M was more difficult to ascertain. In silico 2 
analyses suggest that these variants are possible benign polymorphisms or modifying variants 3 
rather than direct disease-causing mutations.  4 
Noticeably,  we identified the presence of  the two RYR2 SNPs (p.G1885E and p.G1886S) in 5 
a compound heterozygous manner in one additional proband, which were previously reported 6 
to be associated with ARVC/D (data not shown)
24
. However, we also identified this 7 
association in a healthy control subject supporting a possible modifier effect of these variants 8 
rather than a causal role. 9 
The RYR2 mutations identified so far in ARVC/D were located in the cytoplasmic region of 10 
the channel
11,22,23
. Similarly, all the genetic variants we identified were also located in the 11 
cytoplasmic part of the protein, except the p.L4670V variant, which is located into the 12 
transmembrane domain, a hot spot of RYR2 mutations associated with CPVT phenotypes
29
. 13 
We therefore believe that the molecular analyse of RYR2 in ARVC/D requires the screening 14 
of the entire coding region of the gene. 15 
Phenotype/genotype analysis 16 
Until now, only few studies reported RYR2 mutations associated with ARVC/D
11,22,23
 17 
(ARVC2 locus). In those families, the phenotype linked to RYR2 mutations appeared different 18 
from desmosome-related ARVC/D and presented overlapped characteristics with CPVT
11
.  19 
Interestingly, in the present study, the phenotype associated with RYR2 variants is similar to 20 
desmosome-related ARVC/D. Most probands fulfilled ARVC/D diagnosis based on recent 21 
update TFC
25
. They exhibited frequent TWI or parietal block on right precordial leads, which 22 
are common ARVC/D features absent from the CPVT and the ARVC2 phenotype. All 23 
probands displayed ventricular arrhythmias that were predominantly monomorphic with a 24 
LBBB morphology, which is a usual feature of ARVC/D, in opposite to the polymorphic 25 
17 
 
arrhythmias encountered in CPVT or ARVC2. Ventricular effort-induced polymorphic 1 
ventricular arrhythmias are an important diagnosis feature of ARVC2 and CPVT
19,21
, however 2 
this feature was rarely present in our RYR2-related ARVC/D cohort (supplementary table 1). 3 
The p.P1583S carriers exhibited a phenotype closer to ARVC2 with effort-induced ventricular 4 
fibrillation and polymorphic VEc associated with significant RV abnormalities and few 5 
baseline ECG abnormalities.  All patients displayed right ventricular cardiomyopathy with 6 
either RV dilatation and/or WMA usually encountered in ARVC/D. The endocardial mapping 7 
of the proband carrying the putative p.L4670V mutation showed a zone of scar tissue within 8 
the inferior RV wall. One proband developed a severe biventricular cardiomyopathy leading 9 
to heart transplant. The explanted heart showed typical histological features of ARVC/D with 10 
extensive fibro-fatty replacement of myocytes.  11 
Role of RYR2 variants in ARVC/D physiopathology 12 
The Ca
2+ 
release channel RYR2 plays a central role in cardiac excitation-contraction 13 
coupling
30
. During the systole, RYR2 massively releases Ca
2+
 from the sarcoplasmic reticulum 14 
(SR) towards the cytoplasm leading to the cardiac contraction. Recently, a mutation affecting 15 
the phospholamban (PLN gene), another protein playing a central role in calcium regulation, 16 
has been described in an ARVC/D and DCM (dilated cardiomyopathy) population
17
.  17 
Even if the PLN phenotype is possibly particular or overlapping, this observation might 18 
suggest a potential link between [Ca
2+
] dysregulation and arrhythmogenic cardiomyopathies. 19 
It could be hypothesised that modifications of intracellular calcium homeostasis induced by 20 
RYR2 mutations might alter signaling pathways dependent of intracellular Ca
2+
 homeostasis, 21 
and participate to the pathogenesis of ARVC/D. However, this hypothesis requires further 22 
investigations. 23 
 24 
Limits 25 
18 
 
A limit of this study is the absence of definitive demonstration for the pathogenicity of the 1 
RYR2 variants, because of inconclusive segregation analyses and no available functional 2 
studies. However, one of the variants was previously reported to cause a gain of function 
27,28
. 3 
Moreover, the small size of families is quite usual in ARVC/D because of reduced penetrance 4 
and therefore few affected relatives in a family. In addition we performed a careful and 5 
conservative interpretation of the variants. 6 
Another limit concerns the comparison of the rate of RYR2 variants in our cohort and in EVS 7 
cohort while two different methods of sequencing were used, which performance may differ 8 
(error rate, coverage). However, their efficiency in term of error rate seems to be similar
31
 and 9 
the coverage of the coding sequence of RYR2 in EVS was excellent (99.9%). We are therefore 10 
confident with the true difference of RYR2 variants in patients and controls, although the 11 
analysis of a larger cohort of patients with NGS could strengthen our findings.  12 
At last, the ARVC/D probands were selected according to the 1994 Task Force Criteria as this 13 
cohort was prospectively recruited before the publication of the revised TFC.  14 
 15 
CONCLUSION 16 
We performed the first systematic screening of the whole RYR2 gene in a well clinically 17 
characterized ARVC/D cohort, after the exclusion of patients with pathological mutations in 18 
five desmosomal genes, and identified putative RYR2 mutations in 9% of ARVC/D probands. 19 
Furthermore, we observed that RYR2 variants were associated with ARVC/D not overlapping 20 
with CPVT phenotype. This observation suggests that RYR2 variants play a role in the genetic 21 
basis of conventional ARVC/D either as disease-causing mutation, or a modifier gene. This 22 
study also support the notion that in case of a missense variant identified in RYR2 in ARVC/D 23 
patient, it is necessary to be particularly cautious in the interpretation of the pathogenicity of 24 
the variant. The screening of multiple genes, including RYR2, in ARVC/D populations in 25 
19 
 
association with careful phenotype/genotype correlations and functional studies will help to 1 
better understand the complex genetic background of this disease.  2 
 3 
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CLINICAL PERSPECTIVES 1 
To our knowledge, we report here the first systematic screening of the whole RYR2 gene in a 2 
large ARVC/D cohort without mutation in desmosomal genes. We identified six rare RYR2 3 
missense variants predominantly associated with a conventional phenotype of ARVC/D.  4 
Using the data from the Exome Variant Server database, we estimated the prevalence of rare 5 
RYR2 variants to 4% in the general population, which was significantly lower to the 9% 6 
observed in our cohort (Fisher test, p=0.0322). The results support the role of RYR2 gene in 7 
conventional ARVC/D. This study also highlights the fact that in case of a missense variant 8 
identified in RYR2 in ARVC/D patient, it is necessary to be particularly cautious in the 9 
interpretation of the pathogenicity of the variant given the prevalence of rare RYR2 variants in 10 
the general population. The screening of multiple genes, including RYR2, in ARVC/D 11 
populations in association with careful phenotype/genotype correlations and functional 12 
studies will help to better understand the complex genetic background of this disease and to 13 
improve the management of ARVC/D patients in the future.  14 
 15 
16 
26 
 
FIGURE LEGENDS 1 
Figure 1. Family pedigrees of the patients with a RYR2 variant. 2 
Square: male, circle: women, white: unaffected individuals after clinical examination or with 3 
no known disease, black: affected, grey: borderline (TFC 2010). +/-:  heterozygous 4 
individuals, -/-: individuals negative. NA: genetic status not available. aSCD: aborted sudden 5 
cardiac death 6 
 7 
Figure 2. Electrocardiographic characteristics of  RYR2 variants carriers  8 
Proband II:1, family A displayed an unusual intraventricular conduction defect in lead V1 9 
(arrow). Proband II:1 and his sister II:2 from family B and probands from family D and E 10 
displayed T-wave inversion in precordial leads V1 to V3. Proband from family F displays an 11 
iRBBB and epsilon wave in V1 (arrow) and multifocal wide Vec with LBBB morphology. 12 
 13 
Figure 3. Electrophysiological data. 14 
Proband II:1, family B developed spontaneous monomorphic NSVT recorded during the 24-15 
hours ECG monitoring. The electrophysiological study triggered a SVT with LBBB 16 
morphology and superior axis (left), close to the spontaneous ventricular ectopies morphology 17 
(right).  EP study performed on proband II:4, family D triggered NSVT with LBBB 18 
morphology. 19 
 20 
Figure 4. Histological data. 21 
Histological characterisation of the proband from family F. The figure showed typical 22 
fibrofatty replacement in the right ventricle anterior wall of explanted heart (haematoxylin 23 
and eosin staining, x20 and x100 magnification) 24 
 25 
27 
 
Figure 5. Location and conservation of the RYR2 variants identified. 1 
(A) Location: all missense variants are located within the intra-cytoplasmic part or the 2 
protein, at the exception of the p.L4670V, which is located within the trans-membranous part 3 
of the protein
32,33
. (B) The conservation of the mutated residues 1583 and 4670 indicate that 4 
they are highly conserved across human isoforms and species. 5 
 6 
 7 
 8 
Table 1. Clinical characteristics of probands RYR2 mutation carriers.  
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A 
II:1 p.P1583S 22 Pb Europe Aborted SCD none no Yes* 
Dilated RV, apical trabeculations, infero-lateral 
dyskinesia and akinesia of antero lateral RVOT 
(echo, MRI, angiography)** 
Mild LV dilatation 
and infero-basal 
hypokinesia 
Intravaentricular 
conduction defect in 
V1 
3/3* NA BB, ACEi, ICD Affected 
II:3 p.P1583S 17 R Europe none Yes Yes** none 
Mild RV dilatation on echocardiography with 
lowered RV FAC  27% and dyssynchronous RV 
contraction with apico-lateral hypokinesia on 
cardiac-MRI (echo/MRI)  
none 
Terminal QRS 
duration > 55ms in 
V1* 
0/3 NA none Borderline 
I:1 p.P1583S 60 R Europe none none Yes** Yes* 
RV apical akinesia associated with RV enlargement 
(RVOT measured at 34 mm PSAX view) (echo, 
angiography)* 
LVEF = 55% 
AF, Terminal QRS 
duration > 55ms in 
V1* 
0/3 NA BB Affected 
B 
II:1 p.L4670V 43 Pb Europe none none no Yes* 
Mild RV dilatation (RV end-diastolic volume = 109 
ml/m²) and  global hypokinesia  
RV EF 36% (echo,MRI) 
none TWI V1-4** 1/3* NA BB Affected 
II:2 p.L4670V 41 R Europe none Yes Yes** none None (echo,MRI, scintigraphy) none TWI V1-3** 0/3 NA none Affected 
I:2 p.L4670V 70 R Europe none Yes Yes** none None (echo, MRI, scintigraphy) none Normal 2/3* NA none borderline 
C II:3 p.G2367R 59 Pb 
North 
africa 
Presyncope none no Yes* 
WMA with apical and RVOT akinesia, RV LGE* 
(echo, MRI, scintigraphy) 
none 
RBBB;  
QRS V1/6>25ms 
3/3  
QRS>110ms 
NA 
BB, amiodarone, 
ACEi, ICD 
Borderline 
D 
II:4 p.A2213S 35 Pb Europe 
Palpitations 
syncope 
none no Yes* 
RV dilatation (RVOT at 50 mm in PSAX view)  
RV dysfunction (RV FAC : 26 %), apical akinesia 
and infero-basal hypokinesia, RV LGE** (echo, 
MRI) 
LVEF = 55% TWI V1-3** 1/3* NA BB, ICD Affected 
III:1 p.A2213S 12 R Europe none Yes Yes** none None (echo) none Nl 0/3 NA none Unaffected 
E II:2 p.V3219M 41 Pb Europe Presyncope none no Yes* 
WMA with dyskinesia and RV aneurysm (echo, 
MRI) 
none TWI V1-3** 0/3 NA BB borderline 
F 
II:4 p.Y2932H 39 Pb Europe 
Palpitations 
dyspnea 
none no Yes* 
Major RV dilatation, antero akinesia, anterior 
akinesia and infero-apical severe hypokinesia, 
trabeculations (echo, angiography)** 
LVEF = 45%  
Mild LV dilatation 
Epsilon wave, 
incomplete RBBB, 
AF** 
0/3 †** 
Amiodarone, BB, 
ACEi, ICD, Heart 
Tx 
Affected 
II:3 p.Y2932H 41 R Europe none Yes Yes** none None (echo) none Nl 0/3 NA none Unaffected 
II:2 p.Y2932H 42 R Europe none Yes Yes** none None (echo) none Nl 0/3 NA none Unaffected 
ACEi: angiotensin conversion enzyme inhibitor; AF: atrial fibrillation; BB: beta-blockers; Echo: echocardiography; EF: ejection fraction; FAC: fractional area change; Heart 
Tx: heart transplantation;  ICD: implantable cardiac defibrillator; LGE: presence of late-gadolinium enhancement; LV: left ventricle; NA: non-available data; Pb: proband (all 
fulfilled 1994 diagnostic criteria available at enrolment); PSAX: para-sternal short axis; R: relative; RV: right ventricle; RBBB: right bundle branch block; SCD: sudden 
cardiac death; SAECG: signal average ECG; RVOT: right ventricle outflow tract; TWI: T-wave inversion; WMA: wall motion abnormalities; *: min or criteria according to 
the 2010 Task Force Diagnosis Criteria (TFDC); **: major criteria; †: fibrofatty replacement.  
Table
Table 2: Predicted alterations of nonsynonymous changes observed. 
Exon Mutation Location Conservation 
Prediction from bioinformatic tools 
Frequency in variant database* 
SIFT Polyphen2 SNPsandGO 
36 
c.4747C>T 
p.P1583S 
Cytoplasmic yes Intolerant Probably damaging Disease 
 
Not reported in EVS & 1000 genomes      
(but reported in NCBI (frequency 1/24 000)) 
43 
c.6637G>T 
p.A2213S 
Cytoplasmic no Intolerant Possibly damaging Disease Not reported 
46 
c.7099G>A 
p.G2367R 
Cytoplasmic no Tolerant Possibly damaging Neutral 0.008% 
60 
c.8794T>C 
p.Y2932H 
Cytoplasmic no Tolerant Probably damaging Neutral Not reported 
68 
c.9655G>A 
p.V3219M 
Cytoplasmic no Tolerant Possibly damaging Disease 0.008% 
97 
c.14008C>G 
p.L4670V 
Transmembrane domain yes Intolerant Probably damaging Disease Not reported 
 
*Including NCBI, EVS (exome variant server) and 1000 genomes databases 
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